News

The data showed that the compounds demonstrated potent activity against the human-immunodeficiency virus, including non-nucleoside reverse transcriptase inhibitor (NNRTI)- resistant strains, with the potential for improved performance over

The product will be marketed under store brand labels and is comparable to McNeil Consumer Healthcare’s children’s Zyrtec Oral Solution, 1mg/mL, indicated for indoor and outdoor allergy and

Picoplatin, Poniard’s lead product candidate, is a new generation platinum agent designed to overcome platinum resistance. The development of molecular signatures of platinum resistance may allow the prediction

The Phase IIA trial is focused on assessing the safety and efficacy of the oral insulin capsule on 10 type 2 diabetes patients. This study is a continuation

In this study Apoptone inhibited the growth of androgen-independent human tumors LuCaP 35V grown subcutaneously as well as growth of C4-2B cells in the bone environment of castrated

As consideration for exclusive world-wide commercialization rights for Sublinox and OX-NLA, Meda has paid $20 million. Meda has also agreed to the one time milestone payments for each

In the NeuVax (E75) trial 163 patients with breast cancer were enrolled to determine whether the level of HER2 (human epidermal growth factor receptor 2) expression affected response.

Prior to the acquisition, Nutra Pharma owned 38.1% of ReceptoPharm. The acquisition of the remaining interest in Receptopharm provided Nutra Pharma with 100% of the outstanding ReceptoPharm stock

The agreement settles the patent infringement litigation filed by AstraZeneca following Ranbaxy’s submission to the FDA of an abbreviated new drug application for a generic version of Nexium.